Bragar Eagel & Squire is Investigating Certain Officers and Directors of Emergent BioSolutions, Peloton, and Vroom on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- Wall Street flat, IBM results weigh on technology stocks
- Tesla (TSLA) Beats EPS and Revenue Views on Improving Gross Margins, Analysts Praise Very Solid Quarter But Warn of 'Aggressive Valuation' as Stock 'Priced to Perfection'
- Trump Media To Go Public Via $1.7 Billion SPAC Deal, Aims to Fight the Big Tech
- IBM (IBM) Stock Plunges 5% on Sales Miss, Q3 Results Seen as a Setback
- Oil hits multi-year high above $86, then pulls back
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors of Emergent BioSolutions, Inc. (NYSE: EBS), Peloton Interactive, Inc. (NASDAQ: PTON), and Vroom, Inc. (NASDAQ: VRM) on behalf of long-term stockholders. More information about each potential case can be found at the link provided.
Emergent BioSolutions, Inc. (NYSE: EBS)
Bragar Eagel & Squire is investigating certain officers and directors of Emergent BioSolutions, Inc. following a class action complaint that was filed against Emergent BioSolutions on April 19, 2021.
According to the complaint: (1) Emergent’s Baltimore plant had a history of manufacturing issues increasing the likelihood for massive contaminations; (2) these longstanding contamination risks and quality control issues at Emergent's facility led to a string of FDA citations; (3) the Company previously had to discard the equivalent of millions of doses of COVID-19 vaccines after workers at the Baltimore plant deviated from manufacturing standards; and (4) as a result of the foregoing, Defendants’ public statements about Emergent’s ability and capacity to mass manufacture multiple COVID-19 vaccines at its Baltimore manufacturing site were materially false and misleading and lacked a reasonable basis.
Then on, July 30, 2021, Emergent said it has received inquiries and subpoenas from many U.S. authorities related to its abilities to manufacture COVID-19 bulk drug substance.
To learn more about our investigation into Emergent BioSolutions go to: https://bespc.com/cases/EBS
Peloton Interactive, Inc. (NASDAQ: PTON)
Bragar Eagel & Squire is investigating certain officers and directors of Peloton Interactive, Inc. following a class action complaint that was filed against Peloton on April 29, 2021.
The complaint alleges that, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) in addition to the tragic death of a child, Peloton’s Tread+ had caused a serious safety threat to children and pets as there were multiple incidents of injury to both; (2) safety was not a priority to Peloton as defendants were aware of serious injuries and death resulting from the Tread+ yet did not recall or suggest a halt of the use of the Tread+; (3) as a result of the safety concerns, the U.S. Consumer Product Safety Commission (“CPSC”) declared the Tread+ posed a serious risk to public health and safety resulting in its urgent recommendation for consumers with small children to cease using the Tread+; (4) the CPSC also found a safety threat to Tread+ users if they lost their balance; and (5) as a result of the foregoing, defendants’ statements about Peloton’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To learn more about our investigation into Peloton go to: https://bespc.com/cases/PTON
Vroom, Inc. (NASDAQ: VRM)
Bragar Eagel & Squire is investigating certain officers and directors of Vroom, Inc. following a class action complaint that was filed against Vroom on March 22, 2021.
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose that: (1) Vroom had not demonstrated that it was able to control and scale growth in respect to its salesforce to meet the demand for its products; (2) as a result, the Company was forced to discount aged inventory to move through its retail channels or liquidated in its wholesale channels; (3) as a result, the ecommerce gross profit per unit was reasonably likely to decline; and (4) consequently, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To learn more about our investigation into Vroom go to: https://bespc.com/cases/VRM
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- WHL Announces New Partnership With Westland Insurance
- Renewable Energy Group to Release Third Quarter 2021 Financial Results on Wednesday, November 3, 2021
- Republic First Bancorp, Inc. to Report Third Quarter Financial Results on October 27, 2021
Create E-mail Alert Related CategoriesGlobe Newswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!